Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyNeuro-OncologyDiseaseBile Duct CarcinomaColon CancerOvarian TumorPancreatic CancerTumor Biomarker DefinedSubgroupBRAF V600-MutationFGFR2 fusion/rearrangementHER2+IDH1-MutationICD10C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C24.-C24.0C24.1C24.8C24.9C25.-C56MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsColonic NeoplasmsColorectal NeoplasmsCommon Bile Duct NeoplasmsGallbladder NeoplasmsNeoplasmsPancreatic NeoplasmsSequenceNIVO240, Bile Duct Carcinoma, C1-8 (PID2482) -|- NIVO480, C9+ (PID2483).PERT840/TRAS8, colorect. Ca, C1 (PID1533) -|- PERT420/TRAS6, C2+ (PID1534)TOPAZ-1: DURV1500/CISP25/GEMC1000, Bile Duct Carcinoma (PID2145) -|- DURV1500, Maint. (PID2146)ChemotherapyChemo-substanceCapecitabineCisplatinDabrafenibDurvalumabFluorouracilFolinic acidFutibatinibGemcitabineIrinotecanIrinotecan pegylated liposomalIvosidenibLenvatinibNivolumabOxaliplatinPembrolizumabPemigatinibPertuzumabTegafurTrametinibTrastuzumabChemo-substanceCapecitabineCisplatinDabrafenibDurvalumabFluorouracilFolinic acidFutibatinibGemcitabineIrinotecanIrinotecan pegylated liposomalIvosidenibLenvatinibNivolumabOxaliplatinPembrolizumabPemigatinibPertuzumabTegafurTrametinibTrastuzumabChemo-substanceCapecitabineCisplatinDabrafenibDurvalumabFluorouracilFolinic acidFutibatinibGemcitabineIrinotecanIrinotecan pegylated liposomalIvosidenibLenvatinibNivolumabOxaliplatinPembrolizumabPemigatinibPertuzumabTegafurTrametinibTrastuzumabChemo-substanceCapecitabineCisplatinDabrafenibDurvalumabFluorouracilFolinic acidFutibatinibGemcitabineIrinotecanIrinotecan pegylated liposomalIvosidenibLenvatinibNivolumabOxaliplatinPembrolizumabPemigatinibPertuzumabTegafurTrametinibTrastuzumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideNo. Substances1236Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityCholangitisConstipationDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Exanthema, AcneiformFatigueFebrile NeutropeniaHand-Foot SyndromeHeadacheHepatotoxicityHyperbilirubinemiaHypercalcemiaHyperglycemiaHyperphosphatemiaHypertensionHyperthyroidismHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypophysitisHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesInfectionsLeukopeniaMucositisNeuropathyNeutropeniaOral MucositisPainPleural EffusionPneumonitisProteinuriaPyrexiaQTc Time ExtensionRashSepsisTear DropThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorAbou-Alfa GKAndre TEttrich TJGoyal LHe SKelley RKKim RDKim STLamarca ALin JMeric-Bernstam FMorizane COh DYPrimrose JN Ramaswamy ASalama AKSValle JZheng YDiseasefortgeschrittenes oder metastasiertes Gallengangkarzinom, ECOG 0-3Gallengangs-, Ampulla vateri- oder Gallenblasenkarzinom, nicht resezierbar oder rezidiviert, ECOG 0-1, ErstlinientherapieGallengangskarzinom, adjuvant, ECOG 0-3Gallengangskarzinom, metastasiert oder lokal fortgeschritten, IDH1-mutiert, chemotherapierefraktär, ECOG 0-1Gallengangskarzinom, metastasiert oder lokal fortgeschritten, vortherapiert, mit FGFR2-Fusion/-Rearrangement, ECOG 0-2Gallengangskarzinom, vortherapiert, ECOG 0-2Gallengangskarzinom fortgeschritten oder metastasiert, vortherapiert, ECOG 0-1Lokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2lokal fortgeschrittenes oder metastasiertes Gallengangskarzinom, nach Therapie mit Gemcitabin/Cisplatin, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Gallengangskarzinom, nach Therapie mit Gemcitabin/Cisplatin, ECOG 0-2Met. Gallengangkarzinome, ECOG 0-2Metastasiertes oder lokal fortgeschrittenes, nicht resektables Gallengangskarzinom, Erstlinie, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes Gallengangskarzinom, Progress nach gemcitabinhaltiger Chemotherapie, ECOG 0-1Metastasiertes therapieresistentes Kolonkarzinom, Her2 amplifiziert, ECOG 0-2Metastatsiertes Gallengangkarzinome, ECOG 0-2nicht resezierbares, rezidivertes oder metastasiertes Gallengangskarzinom, ECOG 0-2Nicht resezierbares, rezidiviertes oder metastasiertes Gallengangskarzinom, Erstlinie, ECOG 0-2OriginCancer Research UK Clinical Trials Unit, University of Birmingham, BILCAP trialDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FloridaDepartment of Internal Medicine I, University of Ulm, Ulm, Germany, NIFE-AIO-YMO HEP-0315 trialDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA, ClarIDHy trialDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA, FIGHT-202 trialDivision of Hemato-oncology, Sungkyunkwan University School of Medicine, SeoulDivision of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA, KEYNOTE-966 trialDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HFudan University, Shanghai Cancer Center, Minhang Branch, ChinaNational Cancer Center Hospital, Tokyo, Japan, FUGA-BT (JCOG1113)Oncology Department and Digestive Surgery Department, Tenon Hospital, GERCOR studyPeking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, TOPAZ-1 trialStanford University School of Medicine, and the Stanford Cancer Center, Palo Alto, FOENIX-CCA2 trialTata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, GB-SELECTThe Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester, UK, ABC-06 trialThe First Affiliated Hospital of Zhejiang University, Hangzhou, ChinaUniversity College London Cancer Institute, London, UK, ABC-02University of Texas MD Anderson Cancer Center, Houston, USA, MyPathway trialProtocols in Revision 22 protocols foundCapecitabine 1000 / Irinotecan 180, Bile Duct Carcinoma (PID1949 V1.0)Capecitabine 1000 / Oxaliplatin 130, Bile Duct Carcinoma (PID1358 V1.0)Capecitabine 1250, Bile Duct Carcinoma, adjuvant (PID1183 V1.1)Cisplatin 25 / Gemcitabine 1000, Bile Duct Carcinoma (PID577 V1.2)Dabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)Durvalumab 1500 / Cisplatin 25 / Gemcitabine 1000 - Durvalumab 1500, Bile Duct Carcinoma, maintenance (PID2146 V1.0)Durvalumab 1500 / Cisplatin 25 / Gemcitabine 1000, Bile Duct Carcinoma (PID2145 V1.0)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Bile Duct Carcinoma (PID1948 V1.0)Futibatinib 20, Bile Duct Carcinoma (PID2576 V1.0)Gemcitabine 1000 / Tegafur 25, Bile Duct Carcinoma (PID1481 V2.0)GemOx - Gemcitabine 1000 / Oxaliplatin 100, Bile Duct Carcinoma (PID685 V1.0)Irinotecan 240, Bile Duct Carcinoma (PID1954 V1.0)Ivosidenib 500, Bile Duct Carcinoma (PID2367 V1.1)Lenvatinib 12 / Pembrolizumab 200, Bile Duct Carcinoma (PID2481 V1.0)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400, Bile Duct Carcinoma (PID1950 V1.0)Nivolumab 240, Bile Duct Carcinoma, Cycle 1-8 (PID2482 V1.0)Nivolumab 480, Bile Duct Carcinoma, Cycle 9+ (PID2483 V1.0)Pegylated liposomal Irinotecan 70 / Folinic Acid 400 / Fluorouracil 2400, Bile Duct Carcinoma (PID2667 V1.0)Pembrolizumab 200 / Cisplatin 25 / Gemcitabine 1000, Bile Duct Carcinoma (PID2550 V1.0)Pemigatinib 13.5, Bile Duct Carcinoma (PID1787 V1.0)Pertuzumab 420 / Trastuzumab 6, Tumor Biomarker Defined, Cycle 2+ (PID1534 V1.1)Pertuzumab 840 / Trastuzumab 8, Tumor Biomarker Defined, Cycle 1 (PID1533 V1.1)
